MedWatch

ALK reaches symbolic milestone as tablets generate half of revenues

On Thursday, ALK published the best first quarterly report in the allergy company’s history, which also signaled a great future for tablet sales. ”Getting to the halfway point really does something to the company culture,” says CEO Carsten Hellmann.

Carsten Hellmann, CEO of ALK-Abelló | Photo: ALK / PR

On Thursday, ALK-Abelló CEO Carsten Hellman could present a Q1 report that beat analysts’ growth predictions for the allergy firm’s revenue and operating profit.

”It’s nice to see that we have built a growth foundation in ALK, especially considering that the world is relatively turbulent right now. The year’s first quarter is our biggest during the year, and we delivered 13% reported growth and 11% in organic growth. It’s actually the best ever quarter in the company’s history, and the second-best operating result we’ve had,” Hellmann tells MedWatch.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs